|
KR20120123443A
(ko)
*
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
|
|
HRP20181591T1
(hr)
|
2011-06-10 |
2018-11-30 |
Hanmi Science Co., Ltd. |
Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
|
|
TWI601744B
(zh)
|
2011-06-17 |
2017-10-11 |
韓美科學股份有限公司 |
包含調酸素與免疫球蛋白片段之複合物及其用途
|
|
US8951966B2
(en)
|
2011-07-01 |
2015-02-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
|
|
MX354705B
(es)
|
2011-09-23 |
2018-03-16 |
Novo Nordisk As |
Analogos de glucagon novedosos.
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
EA039082B1
(ru)
|
2012-11-06 |
2021-12-01 |
Ханми Фарм. Ко., Лтд. |
Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
|
|
EP3798228A1
(en)
|
2012-11-28 |
2021-03-31 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
MX383664B
(es)
|
2012-12-27 |
2025-03-14 |
Ngm Biopharmaceuticals Inc |
Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
|
|
BR112015025464A2
(pt)
|
2013-04-18 |
2017-10-10 |
Novo Nordisk As |
coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
|
|
DK3004155T3
(da)
*
|
2013-05-28 |
2022-01-03 |
Takeda Pharmaceuticals Co |
Peptidforbindelse
|
|
WO2015035419A1
(en)
*
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
WO2015038938A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
NZ718962A
(en)
|
2013-10-28 |
2019-12-20 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
|
WO2015081891A1
(en)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
|
AR098616A1
(es)
|
2013-12-18 |
2016-06-01 |
Lilly Co Eli |
Péptido para el tratamiento de hipoglicemia severa
|
|
US10039809B2
(en)
|
2013-12-18 |
2018-08-07 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
RS60593B1
(sr)
|
2014-01-24 |
2020-08-31 |
Ngm Biopharmaceuticals Inc |
Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
|
|
TW201625669A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
JP2017525656A
(ja)
|
2014-06-04 |
2017-09-07 |
ノヴォ ノルディスク アー／エス |
医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
|
|
EP3155005A4
(en)
|
2014-06-16 |
2018-07-11 |
NGM Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
EP3177933B1
(en)
*
|
2014-08-06 |
2020-02-19 |
Société des Produits Nestlé S.A. |
Biomarkers for predicting degree of weight loss
|
|
WO2016034186A1
(en)
|
2014-09-05 |
2016-03-10 |
University Of Copenhagen |
Gip peptide analogues
|
|
TWI772252B
(zh)
|
2014-09-16 |
2022-08-01 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
SG11201702757YA
(en)
|
2014-10-23 |
2017-05-30 |
Ngm Biopharmaceuticals Inc |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
|
JP6581656B2
(ja)
|
2014-10-24 |
2019-09-25 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
JP2018012644A
(ja)
*
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
AR103242A1
(es)
*
|
2015-01-09 |
2017-04-26 |
Lilly Co Eli |
Compuestos co-agonistas de gip y glp-1
|
|
KR101669140B1
(ko)
|
2015-04-28 |
2016-10-26 |
(주)케어젠 |
항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
SG10202109721PA
(en)
*
|
2016-03-10 |
2021-10-28 |
Medimmune Ltd |
Glucagon and glp-1 co-agonists for the treatment of obesity
|
|
EP3467106B1
(en)
|
2016-05-24 |
2025-07-09 |
Takeda Pharmaceutical Company Limited |
Peptide compound
|
|
US11370841B2
(en)
|
2016-08-26 |
2022-06-28 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
CN109200273B
(zh)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
一种多肽用于制备预防或治疗脂肪肝病药物的用途
|
|
JOP20190211A1
(ar)
|
2017-03-31 |
2019-09-15 |
Takeda Pharmaceuticals Co |
ببتيد منشط لمستقبل gip
|
|
US11572399B2
(en)
|
2017-05-31 |
2023-02-07 |
University Of Copenhagen |
Long-acting GIP peptide analogues
|
|
US10470311B2
(en)
*
|
2017-09-28 |
2019-11-05 |
Juniper Networks, Inc. |
Clearance size reduction for backdrilled differential vias
|
|
CA3078652A1
(en)
|
2017-10-12 |
2019-04-18 |
Novo Nordisk A/S |
Semaglutide in medical therapy
|
|
PE20210473A1
(es)
|
2018-05-04 |
2021-03-08 |
Novo Nordisk As |
Derivados de gip y usos de estos
|
|
KR20250044806A
(ko)
*
|
2018-07-23 |
2025-04-01 |
일라이 릴리 앤드 캄파니 |
요법을 위한 gip/glp1 공효능제 사용 방법
|
|
US12187773B2
(en)
|
2018-12-03 |
2025-01-07 |
Antag Therapeutics Aps |
Modified GIP peptide analogues
|
|
CN109379770B
(zh)
*
|
2018-12-11 |
2021-04-06 |
北京百瑞互联技术有限公司 |
蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点
|
|
WO2020143625A1
(zh)
|
2019-01-07 |
2020-07-16 |
鸿绪生物医药科技（北京）有限公司 |
新型多肽及其治疗用途
|
|
WO2021083306A1
(zh)
*
|
2019-10-31 |
2021-05-06 |
东莞市东阳光生物药研发有限公司 |
Glp-1/gcg双受体激动剂多肽
|
|
EP4069726A4
(en)
|
2019-12-04 |
2024-03-20 |
The Scripps Research Institute |
GLP2 RECEPTOR AGONISTS AND METHOD OF USE
|
|
EP4112637A4
(en)
*
|
2020-02-24 |
2024-04-03 |
Shenzhen Turier Biotech Co., Ltd. |
POLYPEPTIDE COMPOUND AND ITS APPLICATION IN THE PREVENTION OR TREATMENT OF DIABETES OR A COMPLICATION OF DIABETES
|
|
CN118754965A
(zh)
|
2020-05-29 |
2024-10-11 |
北京拓界生物医药科技有限公司 |
Glp-1和gip受体双重激动剂化合物及其应用
|
|
AU2021304762B2
(en)
*
|
2020-07-06 |
2024-05-02 |
Vitalixir (Beijing) Co., Ltd |
Novel polypeptide and therapeutic use thereof
|
|
AU2021312323A1
(en)
*
|
2020-07-22 |
2023-02-02 |
Novo Nordisk A/S |
Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
|
|
JP2023534130A
(ja)
*
|
2020-07-22 |
2023-08-08 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
|
|
JP2023537895A
(ja)
*
|
2020-08-14 |
2023-09-06 |
ハンミ ファーマシューティカル カンパニー リミテッド |
三重活性体持続型結合体を有効成分として含む薬学組成物
|
|
KR20220050820A
(ko)
|
2020-10-16 |
2022-04-25 |
한미약품 주식회사 |
Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
|
|
CN116583533A
(zh)
*
|
2020-10-16 |
2023-08-11 |
韩美药品株式会社 |
Gip衍生物、其长效缀合物和包括其的药物组合物
|
|
MX2023006419A
(es)
*
|
2020-12-02 |
2023-08-15 |
Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd |
Compuestos polipéptidos modificados con lactama.
|
|
CN114891071A
(zh)
*
|
2020-12-08 |
2022-08-12 |
鸿绪生物科技(嘉善)有限公司 |
新型多肽及其治疗用途
|
|
CN114617956B
(zh)
*
|
2020-12-10 |
2023-10-03 |
江苏中新医药有限公司 |
一种高效降糖的蛋白质药物
|
|
KR20240007251A
(ko)
|
2021-05-13 |
2024-01-16 |
카모트 테라퓨틱스, 인크. |
G-단백질 결합 수용체의 조절제
|
|
AU2022289610A1
(en)
*
|
2021-06-09 |
2024-01-25 |
The Scripps Research Institute |
Long-acting dual gip/glp-1 peptide conjugates and methods of use
|
|
CN118103391A
(zh)
*
|
2021-11-12 |
2024-05-28 |
福建盛迪医药有限公司 |
Glp-1受体和gip受体双重激动剂的药物组合物及其用途
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
CN116712530B
(zh)
*
|
2023-02-03 |
2024-03-08 |
江苏师范大学 |
一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
|
|
US20240366728A1
(en)
*
|
2023-04-23 |
2024-11-07 |
Carmot Therapeutics Inc. |
Treatment of Diabetes Mellitus
|
|
WO2026046202A1
(zh)
*
|
2024-08-26 |
2026-03-05 |
博瑞生物医药（苏州）股份有限公司 |
Glp-1/gip肽或含有其的药物组合物的用途
|
|
WO2026046328A1
(en)
*
|
2024-08-30 |
2026-03-05 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Dosing regimen of glp-1 conjugates
|